Clinical trial

RGL-270 + ICI in Advanced NSCLC

NCT07652125

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-10-25

PhaseNA

Study timeline

Study start (actual)2025-10-25Date precision: day

Registry last updated2026-06-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Interventions

RGL-270 in Combination with PD-1/PD-L1 InhibitorsBIOLOGICAL

Physician's Choice SOCOTHER

Sponsors & collaborators

Guangdong Association of Clinical Trialslead sponsor

Shanghai Regenelead Theraples,Co,Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07652125 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.